Therapeutic Targets in Inflammatory Bowel Disease: Current and Future
暂无分享,去创建一个
[1] S. Rose-John,et al. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. , 2015, Current opinion in immunology.
[2] R. Maciuca,et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies , 2015, Thorax.
[3] C. Klein,et al. Very Early-onset Inflammatory Bowel Disease: Gaining Insight Through Focused Discovery , 2015, Gastroenterology & hepatology.
[4] H. Kettenberger,et al. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics , 2015, Proceedings of the National Academy of Sciences.
[5] S. Vermeire,et al. 901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT Study , 2015 .
[6] S. Vermeire,et al. 445 The TOUCHSTONE Study: a Randomized, Double-Blind, Placebo-Controlled Induction Trial of an Oral S1P Receptor Modulator (RPC1063) in Moderate to Severe Ulcerative Colitis , 2015 .
[7] A. Amiot,et al. 829 Long-Term Outcomes in a Cohort of Patients With Acute Severe Ulcerative Colitis Refractory to Intravenous Steroids Treated With Cyclosporine or Infliximab , 2015 .
[8] D. Clemmons,et al. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. , 2015, Gastroenterology.
[9] S. Hanauer,et al. Briakinumab for Treatment of Crohn's Disease: Results of a Randomized Trial , 2015, Inflammatory bowel diseases.
[10] Maria Fichera,et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. , 2015, The New England journal of medicine.
[11] Graham M Lord,et al. Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease , 2015, Gut.
[12] M. Fujimiya,et al. Stem cell therapy for inflammatory bowel disease , 2015, Journal of Gastroenterology.
[13] W. Reinisch,et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study , 2015, Gut.
[14] A. Kaser,et al. Role of endoplasmic reticulum stress and autophagy as interlinking pathways in the pathogenesis of inflammatory bowel disease , 2015, Current opinion in gastroenterology.
[15] M. Vandervoort,et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity , 2015, Alimentary pharmacology & therapeutics.
[16] Dan Knights,et al. Complex host genetics influence the microbiome in inflammatory bowel disease , 2014, Genome Medicine.
[17] M. Murad,et al. Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis , 2014, Inflammatory bowel diseases.
[18] L. Peyrin-Biroulet,et al. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study , 2014, Gut.
[19] C. Yu,et al. TNFSF15 is an independent predictor for the development of Crohn's disease-related complications in Koreans. , 2014, Journal of Crohn's & colitis.
[20] S. Bombardieri,et al. A phase IB clinical trial with Dekavil (F8-IL10), an immunoregulatory 'armed antibody' for the treatment of rheumatoid arthritis, used in combination wiIh methotrexate. , 2014, The Israel Medical Association journal : IMAJ.
[21] K. Taylor,et al. Association of NOD2 and IL23R with Inflammatory Bowel Disease in Puerto Rico , 2014, PloS one.
[22] W. Sandborn,et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[23] C. Bain,et al. Macrophages in intestinal homeostasis and inflammation , 2014, Immunological reviews.
[24] Sarah Spiegel,et al. Sphingolipid metabolites in inflammatory disease , 2014, Nature.
[25] S. Targan,et al. Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis , 2014, Mucosal Immunology.
[26] Xin Chen,et al. Th17 cells and Tregs: unlikely allies , 2014, Journal of leukocyte biology.
[27] A. Kostic,et al. The microbiome in inflammatory bowel disease: current status and the future ahead. , 2014, Gastroenterology.
[28] J. Däbritz. Granulocyte macrophage colony-stimulating factor and the intestinal innate immune cell homeostasis in Crohn's disease. , 2014, American journal of physiology. Gastrointestinal and liver physiology.
[29] Se Jin Song,et al. The treatment-naive microbiome in new-onset Crohn's disease. , 2014, Cell host & microbe.
[30] Désirée van der Heijde,et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial , 2013, The Lancet.
[31] R. Cabezón,et al. Therapeutic Potential of Tolerogenic Dendritic Cells in IBD: From Animal Models to Clinical Application , 2013, Clinical & developmental immunology.
[32] A. Segal,et al. What Is Wrong with Granulocytes in Inflammatory Bowel Diseases? , 2013, Digestive Diseases.
[33] W. Garrett,et al. The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic Treg Cell Homeostasis , 2013, Science.
[34] Yusun Jung,et al. Genome-wide association study of Crohn's disease in Koreans revealed three new susceptibility loci and common attributes of genetic susceptibility across ethnic populations , 2013, Gut.
[35] M. Hattori,et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota , 2013, Nature.
[36] S. Targan,et al. Multidimensional Prognostic Risk Assessment Identifies Association Between IL12B Variation and Surgery in Crohn’s Disease , 2013, Inflammatory bowel diseases.
[37] S. Targan,et al. SUSTAINED TL1A (TNFSF15) EXPRESSION ON BOTH LYMPHOID AND MYELOID CELLS LEADS TO MILD SPONTANEOUS INTESTINAL INFLAMMATION AND FIBROSIS. , 2013, European journal of microbiology & immunology.
[38] Yusuke Nakamura,et al. Association Study of 71 European Crohn's Disease Susceptibility Loci in a Japanese Population , 2013, Inflammatory bowel diseases.
[39] B. Hartmann,et al. Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. , 2013, The Journal of allergy and clinical immunology.
[40] D. M. van der Heijde,et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial , 2013, Annals of the rheumatic diseases.
[41] M. Silverberg,et al. IL-10R Polymorphisms Are Associated with Very-early-onset Ulcerative Colitis , 2013, Inflammatory bowel diseases.
[42] J. González,et al. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project , 2012, Gut.
[43] L. Biancone,et al. A phase 1 open‐label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease , 2012, Alimentary pharmacology & therapeutics.
[44] A. Foussat,et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. , 2012, Gastroenterology.
[45] G. Greenberg,et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. , 2012, The New England journal of medicine.
[46] W. Sandborn,et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. , 2012, The New England journal of medicine.
[47] J. Puchalka,et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. , 2012, Gastroenterology.
[48] D. Mould,et al. Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose‐ranging Study , 2012, Inflammatory bowel diseases.
[49] J. Macdonald,et al. Sargramostim (GM‐CSF) for Induction of Remission in Crohn's Disease: A Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Systematic Review of Randomized Trials , 2012, Inflammatory bowel diseases.
[50] Marc Vandemeulebroecke,et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial , 2012, Gut.
[51] R. Plenge,et al. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. , 2012, Immunity.
[52] S. Targan,et al. Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis. , 2012, The American journal of pathology.
[53] L. Honigberg,et al. Functional Studies on the IBD Susceptibility Gene IL23R Implicate Reduced Receptor Function in the Protective Genetic Variant R381Q , 2011, PloS one.
[54] T. Mizushima,et al. Therapeutic Effects of Novel Sphingosine-1-Phosphate Receptor Agonist W-061 in Murine DSS Colitis , 2011, PloS one.
[55] J. Scheller,et al. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. , 2011, The Journal of clinical investigation.
[56] H. Ogata,et al. Regulatory T cells suppress development of colitis, blocking differentiation of T-helper 17 into alternative T-helper 1 cells. , 2011, Gastroenterology.
[57] F. Rieux-Laucat,et al. Defective IL10 Signaling Defining a Subgroup of Patients With Inflammatory Bowel Disease , 2011, The American Journal of Gastroenterology.
[58] P. Rutgeerts,et al. Mucosal Gene Expression of Cell Adhesion Molecules, Chemokines, and Chemokine Receptors in Patients With Inflammatory Bowel Disease Before and After Infliximab Treatment , 2011, The American Journal of Gastroenterology.
[59] Ke Wu,et al. IL-17+ Regulatory T Cells in the Microenvironments of Chronic Inflammation and Cancer , 2011, The Journal of Immunology.
[60] Steven W. Martin,et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study , 2011, Gut.
[61] K. Honda,et al. Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species , 2011, Science.
[62] S. Targan,et al. Constitutive TL1A (TNFSF15) Expression on Lymphoid or Myeloid Cells Leads to Mild Intestinal Inflammation and Fibrosis , 2011, PloS one.
[63] P. Vandamme,et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives , 2011, Gut.
[64] A. Testori,et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. , 2010, Blood.
[65] B. Psaty,et al. Genetic predictors of medically refractory ulcerative colitis , 2010, Inflammatory bowel diseases.
[66] N. Sebire,et al. Infant colitis—it's in the genes , 2010, The Lancet.
[67] F. Powrie,et al. Interleukin-23 Drives Intestinal Inflammation through Direct Activity on T Cells , 2010, Immunity.
[68] D. McKay,et al. In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. , 2010, Gastroenterology.
[69] J. Myśliwska,et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. , 2009, Clinical immunology.
[70] G. Corazza,et al. Differential regulation of interleukin 17 and interferon γ production in inflammatory bowel disease , 2009, Gut.
[71] Richard A Flavell,et al. A protective function for interleukin 17A in T cell–mediated intestinal inflammation , 2009, Nature Immunology.
[72] Joseph T. Glessner,et al. Genome wide association (GWA) predictors of anti‐TNF&agr; therapeutic responsiveness in pediatric inflammatory bowel disease , 2009, Inflammatory bowel diseases.
[73] N. Pullen,et al. Pharmacological characterization of PF‐00547659, an anti‐human MAdCAM monoclonal antibody , 2009, British journal of pharmacology.
[74] T. Mcclanahan,et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivo , 2009, Nature Immunology.
[75] J. Hugot,et al. TNFSF15 Polymorphisms Are Associated With Susceptibility to Inflammatory Bowel Disease in a New European Cohort , 2009, The American Journal of Gastroenterology.
[76] Y. Hannun,et al. A role for sphingosine kinase 1 in dextran sulfate sodium‐induced colitis , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[77] T. Okanoue,et al. Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. , 2008, Biochemical and biophysical research communications.
[78] A. Cohen,et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[79] S. Snapper,et al. Regulatory T cells in inflammatory bowel disease , 2008, Current opinion in gastroenterology.
[80] W. Strober,et al. THE ROLE OF IL-13 AND NK T CELLS IN EXPERIMENTAL AND HUMAN ULCERATIVE COLITIS , 2008, Mucosal Immunology.
[81] P. Rutgeerts,et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. , 2008, Gastroenterology.
[82] T. Hibi,et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease , 2008, Gut.
[83] T. Nishida,et al. A Novel Sphingosine 1-Phosphate Receptor Agonist, 2-Amino-2-propanediol Hydrochloride (KRP-203), Regulates Chronic Colitis in Interleukin-10 Gene-Deficient Mice , 2008, Journal of Pharmacology and Experimental Therapeutics.
[84] Javier Martín,et al. Replication of an association between IL23R gene polymorphism with inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[85] Iwona Wrobel,et al. IL‐23 receptor (IL‐23R) gene protects against pediatric Crohn's disease , 2007, Inflammatory bowel diseases.
[86] P. Deloukas,et al. IL23R Variation Determines Susceptibility But Not Disease Phenotype in Inflammatory Bowel Disease , 2007, Gastroenterology.
[87] Judy H. Cho,et al. A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.
[88] M. Marinaro,et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. , 2006, Gastroenterology.
[89] J. Wehkamp,et al. Paneth cells and the innate immune response , 2006, Current opinion in gastroenterology.
[90] O. Inatomi,et al. The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice. , 2006, Oncology reports.
[91] Erik Remaut,et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[92] J. Ragoussis,et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. , 2005, Human molecular genetics.
[93] G. Federici,et al. Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease. , 2005, Gastroenterology.
[94] A. Cohen,et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.
[95] J. Korzenik,et al. Sargramostim for active Crohn's disease. , 2005, The New England journal of medicine.
[96] T. Macdonald,et al. Immunity, Inflammation, and Allergy in the Gut , 2005, Science.
[97] J. Korzenik,et al. An open‐labelled study of granulocyte colony‐stimulating factor in the treatment of active Crohn's disease , 2005, Alimentary pharmacology & therapeutics.
[98] S. V. van Deventer,et al. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis , 2004, Gut.
[99] T. Hibi,et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. , 2004, Gastroenterology.
[100] K. Shuai,et al. Regulation of JAK–STAT signalling in the immune system , 2003, Nature Reviews Immunology.
[101] B. Malissen,et al. Selective Generation of Gut Tropic T Cells in Gut-associated Lymphoid Tissue (GALT) , 2003, The Journal of experimental medicine.
[102] Jean Paul Remon,et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10 , 2003, Nature Biotechnology.
[103] J. Massagué,et al. Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.
[104] K. Asadullah,et al. Interleukin-10 Therapy—Review of a New Approach , 2003, Pharmacological Reviews.
[105] Y. Tabata,et al. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease. , 2003, Journal of gastroenterology.
[106] A. Andoh,et al. Increased expression of interleukin 17 in inflammatory bowel disease , 2003, Gut.
[107] J. Korzenik,et al. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor , 2002, The Lancet.
[108] A. Buchman,et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease , 2002, Gut.
[109] Mourad Sahbatou,et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.
[110] Judy H. Cho,et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.
[111] E. Hahn,et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. , 2001, Gastroenterology.
[112] S. Targan,et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. , 2001, Gastroenterology.
[113] S. Targan,et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics , 2000, Gut.
[114] W. Strober,et al. Treatment of Experimental (Trinitrobenzene Sulfonic Acid) Colitis by Intranasal Administration of Transforming Growth Factor (Tgf)-β1 Plasmid , 2000, The Journal of Experimental Medicine.
[115] J. Korzenik,et al. Is Crohn's Disease an Immunodeficiency? , 2000, Digestive Diseases and Sciences.
[116] C. Elia,et al. Expression of lymphocyte-endothelial receptor-ligand pairs, α4β7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease , 1999, Gut.
[117] H. Okamura,et al. Immunoregulatory roles of IL-10 in innate immunity: IL-10 inhibits macrophage production of IFN-gamma-inducing factors but enhances NK cell production of IFN-gamma. , 1998, Journal of immunology.
[118] J. Panés,et al. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. , 1998, Gastroenterology.
[119] K. Sullivan,et al. Course of Crohn's disease after allogeneic marrow transplantation. , 1998, Gastroenterology.
[120] B. Ludviksson,et al. Reciprocal IFN-γ and TGF-β responses regulate the occurrence of mucosal inflammation , 1997 .
[121] R. Coffman,et al. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells , 1996, The Journal of experimental medicine.
[122] J. Fell,et al. The distribution of dividing T cells throughout the intestinal wall in inflammatory bowel disease (IBD) , 1996, Clinical and experimental immunology.
[123] K. Rajewsky,et al. Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.
[124] R. Macdermott,et al. Enhand secretion of tumour necrosis factor‐alpha, IL‐6, and IL‐1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease , 1993 .
[125] J. Schölmerich,et al. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. , 1992, Gastroenterology.
[126] S. Targan,et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. , 1990, The Journal of allergy and clinical immunology.
[127] R. Okamoto,et al. Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease , 2015, Journal of Gastroenterology.
[128] R. Herrmann,et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[129] David C. Wilson,et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease , 2012, Nature.
[130] C. Mackay,et al. Diet, gut microbiota and immune responses , 2010, Nature Immunology.
[131] B. Becher,et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. , 2009, Gastroenterology.
[132] A. Andoh,et al. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. , 2004, Clinical immunology.
[133] H. Tilg,et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. , 2002, Gut.
[134] P. Rutgeerts,et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. , 1999, Gastroenterology.